Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gartrell

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
The Journal of Urology|May 1, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)Ashesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
World Journal of Urology|May 25, 2012
Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United StatesAlexander C Small, Che-Kai Tsao, Erin L Moshier, et al.
European Urology Oncology|February 21, 2023
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder CancerBrant A Inman, Noah M Hahn, Kelly Stratton, et al.
Clinical Genitourinary Cancer|June 2, 2012
Trends in the use of cytoreductive nephrectomy in the United StatesChe-Kai Tsao, Alexander C Small, Erin L Moshier, et al.
World Journal of Urology|December 11, 2012
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysisChe-kai Tsao, Alexander C Small, Max Kates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate CancerAlicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
European Urology Oncology|December 28, 2023
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant ChemotherapyPetros Grivas, Vadim S Koshkin, Xiangying Chu, et al.
Journal of Pediatric Surgery|March 11, 2023
Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival: An Observational StudyAndrew M Fleming, Andrew J Murphy, Suraj Sarvode Mothi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2021
Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancerRitesh K Aggarwal, Rebecca A Luchtel, Venkata Machha, et al.
European Urology Oncology|April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trialDaniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
The Journal of Urology|May 1, 2023
Diagnostic Performance and Safety of <sup>18</sup>F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)Ashesh B Jani, Gregory C Ravizzini, Benjamin A Gartrell, et al.
World Journal of Urology|May 25, 2012
Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United StatesAlexander C Small, Che-Kai Tsao, Erin L Moshier, et al.
European Urology Oncology|February 21, 2023
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder CancerBrant A Inman, Noah M Hahn, Kelly Stratton, et al.
Clinical Genitourinary Cancer|June 2, 2012
Trends in the use of cytoreductive nephrectomy in the United StatesChe-Kai Tsao, Alexander C Small, Erin L Moshier, et al.
World Journal of Urology|December 11, 2012
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysisChe-kai Tsao, Alexander C Small, Max Kates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate CancerAlicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
European Urology Oncology|December 28, 2023
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant ChemotherapyPetros Grivas, Vadim S Koshkin, Xiangying Chu, et al.
Journal of Pediatric Surgery|March 11, 2023
Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival: An Observational StudyAndrew M Fleming, Andrew J Murphy, Suraj Sarvode Mothi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2021
Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancerRitesh K Aggarwal, Rebecca A Luchtel, Venkata Machha, et al.
European Urology Oncology|April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trialDaniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Pageof 5